Desmoglein-2 as a prognostic and biomarker in ovarian cancer
Jiho Kim, Peter G. Beidler, Hongjie Wang, Chang Li, Abdullah Quassab, Cari Coles, Charles W. Drescher, Darrick Carter, André Lieber
Abstract
studies indicate that non-cytotoxic doses of cisplatin can enhance DSG2 expression, which, in turn, can contribute to chemo-resistance. We suggest that DSG2 can be used in stratifying patients, deciding on where to use aggressive treatment strategies, predicting chemoresistance, and as a companion diagnostic for treatments targeting DSG2.
Topics & Concepts
Ovarian cancerMedicineImmunohistochemistryCancerInternal medicineOncologyBiomarkerMetastasisCisplatinChemotherapyCancer researchPathologyBiologyBiochemistryWnt/β-catenin signaling in development and cancerHeat shock proteins researchOvarian cancer diagnosis and treatment